Consolidated Statements of Stockholders' Equity - USD ($)	Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Chief Executive Officer [Member]	Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Helomics Holding Corp. [Member]	Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Private Placement [Member]	Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Over-Allotment Option [Member]	Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Equity Line Purchase Agreement [Member]	Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Series E Warrants [Member]	Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Re-priced Warrants [Member]	Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Warrants Issued With Promissory Note [Member]	Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Warrants Issued to CEO [Member]	Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Bridge Loan Warrants [Member]	Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Warrants Issued to Helomics' Investors [Member]	Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Note Payable Warrants [Member]	Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Warrants Held by Noteholders [Member]	Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Bridge Notes [Member]	Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Bridge Loan Agreement [Member]	Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Promissory Note [Member]	Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Consulting Agreement One [Member]	Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Contract with TumorGenesis [Member]	Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Investor Relations Consultant [Member]	Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Converison of Bridge Loan to Common Stock [Member]	Preferred Stock [Member] Series B Convertible Preferred Stock [Member]	Preferred Stock [Member] Series D Convertible Preferred Stock [Member] Chief Executive Officer [Member]	Preferred Stock [Member] Series D Convertible Preferred Stock [Member] Private Placement [Member]	Preferred Stock [Member] Series D Convertible Preferred Stock [Member] Equity Line Purchase Agreement [Member]	Preferred Stock [Member] Series D Convertible Preferred Stock [Member] Warrants Issued With Promissory Note [Member]	Preferred Stock [Member] Series D Convertible Preferred Stock [Member] Warrants Issued to CEO [Member]	Preferred Stock [Member] Series D Convertible Preferred Stock [Member] Warrants Issued to Helomics' Investors [Member]	Preferred Stock [Member] Series D Convertible Preferred Stock [Member] Warrants Held by Noteholders [Member]	Preferred Stock [Member] Series D Convertible Preferred Stock [Member] Bridge Notes [Member]	Preferred Stock [Member] Series D Convertible Preferred Stock [Member] Bridge Loan Agreement [Member]	Preferred Stock [Member] Series D Convertible Preferred Stock [Member] Promissory Note [Member]	Preferred Stock [Member] Series D Convertible Preferred Stock [Member] Investor Relations Consultant [Member]	Preferred Stock [Member] Series D Convertible Preferred Stock [Member]	Preferred Stock [Member] Series E Convertible Preferred Stock [Member] Chief Executive Officer [Member]	Preferred Stock [Member] Series E Convertible Preferred Stock [Member] Private Placement [Member]	Preferred Stock [Member] Series E Convertible Preferred Stock [Member] Equity Line Purchase Agreement [Member]	Preferred Stock [Member] Series E Convertible Preferred Stock [Member] Warrants Issued With Promissory Note [Member]	Preferred Stock [Member] Series E Convertible Preferred Stock [Member] Warrants Issued to CEO [Member]	Preferred Stock [Member] Series E Convertible Preferred Stock [Member] Warrants Issued to Helomics' Investors [Member]	Preferred Stock [Member] Series E Convertible Preferred Stock [Member] Warrants Held by Noteholders [Member]	Preferred Stock [Member] Series E Convertible Preferred Stock [Member] Bridge Notes [Member]	Preferred Stock [Member] Series E Convertible Preferred Stock [Member] Bridge Loan Agreement [Member]	Preferred Stock [Member] Series E Convertible Preferred Stock [Member] Promissory Note [Member]	Preferred Stock [Member] Series E Convertible Preferred Stock [Member] Investor Relations Consultant [Member]	Preferred Stock [Member] Series E Convertible Preferred Stock [Member]	Preferred Stock [Member] Series C Convertible Preferred Stock [Member] Helomics Holding Corp. [Member]	Preferred Stock [Member] Series C Convertible Preferred Stock [Member] Over-Allotment Option [Member]	Preferred Stock [Member] Series C Convertible Preferred Stock [Member] Series E Warrants [Member]	Preferred Stock [Member] Series C Convertible Preferred Stock [Member] Re-priced Warrants [Member]	Preferred Stock [Member] Series C Convertible Preferred Stock [Member] Bridge Loan Warrants [Member]	Preferred Stock [Member] Series C Convertible Preferred Stock [Member] Note Payable Warrants [Member]	Preferred Stock [Member] Series C Convertible Preferred Stock [Member] Consulting Agreement One [Member]	Preferred Stock [Member] Series C Convertible Preferred Stock [Member] Contract with TumorGenesis [Member]	Preferred Stock [Member] Series C Convertible Preferred Stock [Member] Converison of Bridge Loan to Common Stock [Member]	Preferred Stock [Member] Series C Convertible Preferred Stock [Member]	Common Stock [Member] Chief Executive Officer [Member]	Common Stock [Member] Helomics Holding Corp. [Member]	Common Stock [Member] Private Placement [Member]	Common Stock [Member] Over-Allotment Option [Member]	Common Stock [Member] Equity Line Purchase Agreement [Member]	Common Stock [Member] Series E Warrants [Member]	Common Stock [Member] Re-priced Warrants [Member]	Common Stock [Member] Warrants Issued With Promissory Note [Member]	Common Stock [Member] Warrants Issued to CEO [Member]	Common Stock [Member] Bridge Loan Warrants [Member]	Common Stock [Member] Warrants Issued to Helomics' Investors [Member]	Common Stock [Member] Note Payable Warrants [Member]	Common Stock [Member] Warrants Held by Noteholders [Member]	Common Stock [Member] Bridge Notes [Member]	Common Stock [Member] Bridge Loan Agreement [Member]	Common Stock [Member] Promissory Note [Member]	Common Stock [Member] Consulting Agreement One [Member]	Common Stock [Member] Contract with TumorGenesis [Member]	Common Stock [Member] Investor Relations Consultant [Member]	Common Stock [Member] Converison of Bridge Loan to Common Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member] Chief Executive Officer [Member]	Additional Paid-in Capital [Member] Helomics Holding Corp. [Member]	Additional Paid-in Capital [Member] Private Placement [Member]	Additional Paid-in Capital [Member] Over-Allotment Option [Member]	Additional Paid-in Capital [Member] Equity Line Purchase Agreement [Member]	Additional Paid-in Capital [Member] Series E Warrants [Member]	Additional Paid-in Capital [Member] Re-priced Warrants [Member]	Additional Paid-in Capital [Member] Warrants Issued With Promissory Note [Member]	Additional Paid-in Capital [Member] Warrants Issued to CEO [Member]	Additional Paid-in Capital [Member] Bridge Loan Warrants [Member]	Additional Paid-in Capital [Member] Warrants Issued to Helomics' Investors [Member]	Additional Paid-in Capital [Member] Note Payable Warrants [Member]	Additional Paid-in Capital [Member] Warrants Held by Noteholders [Member]	Additional Paid-in Capital [Member] Bridge Notes [Member]	Additional Paid-in Capital [Member] Bridge Loan Agreement [Member]	Additional Paid-in Capital [Member] Promissory Note [Member]	Additional Paid-in Capital [Member] Consulting Agreement One [Member]	Additional Paid-in Capital [Member] Contract with TumorGenesis [Member]	Additional Paid-in Capital [Member] Investor Relations Consultant [Member]	Additional Paid-in Capital [Member] Converison of Bridge Loan to Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member] Chief Executive Officer [Member]	Retained Earnings [Member] Helomics Holding Corp. [Member]	Retained Earnings [Member] Private Placement [Member]	Retained Earnings [Member] Over-Allotment Option [Member]	Retained Earnings [Member] Equity Line Purchase Agreement [Member]	Retained Earnings [Member] Series E Warrants [Member]	Retained Earnings [Member] Re-priced Warrants [Member]	Retained Earnings [Member] Warrants Issued With Promissory Note [Member]	Retained Earnings [Member] Warrants Issued to CEO [Member]	Retained Earnings [Member] Bridge Loan Warrants [Member]	Retained Earnings [Member] Warrants Issued to Helomics' Investors [Member]	Retained Earnings [Member] Note Payable Warrants [Member]	Retained Earnings [Member] Warrants Held by Noteholders [Member]	Retained Earnings [Member] Bridge Notes [Member]	Retained Earnings [Member] Bridge Loan Agreement [Member]	Retained Earnings [Member] Promissory Note [Member]	Retained Earnings [Member] Consulting Agreement One [Member]	Retained Earnings [Member] Contract with TumorGenesis [Member]	Retained Earnings [Member] Investor Relations Consultant [Member]	Retained Earnings [Member] Converison of Bridge Loan to Common Stock [Member]	Retained Earnings [Member]	Chief Executive Officer [Member]	Helomics Holding Corp. [Member]	Private Placement [Member]	Over-Allotment Option [Member]	Equity Line Purchase Agreement [Member]	Series E Warrants [Member]	Re-priced Warrants [Member]	Warrants Issued With Promissory Note [Member]	Warrants Issued to CEO [Member]	Bridge Loan Warrants [Member]	Warrants Issued to Helomics' Investors [Member]	Note Payable Warrants [Member]	Warrants Held by Noteholders [Member]	Bridge Notes [Member]	Bridge Loan Agreement [Member]	Promissory Note [Member]	Consulting Agreement One [Member]	Contract with TumorGenesis [Member]	Investor Relations Consultant [Member]	Converison of Bridge Loan to Common Stock [Member]	Total
Balance (in shares) at Dec. 31, 2017																					79,246																																		647,819																					694,328
Balance at Dec. 31, 2017																					$ 792																																		$ 6,479																					$ 6,943																					$ 55,699,169																					$ (53,021,469)																					$ 2,691,914
Preferred conversion to common shares pursuant to private placement agreement (in shares)																																																							(647,819)
Preferred conversion to common shares pursuant to private placement agreement																																																							$ (6,479)																																																																																				(6,479)
Preferred conversion to common shares pursuant to private placement agreement (in shares)																																																																											65,000	58,975
Preferred conversion to common shares pursuant to private placement agreement																																																																											$ 650	$ 590																				$ 205,955	5,889																																									$ 206,605
Shares issued (in shares)																																																											21,525																	290,000
Shares issued																																																											$ 215																	$ 2,900				$ 204,206																	2,752,187				$ 1																					$ 204,422																	2,755,087
Investment in Subsidiary pursuant to Helomics 20% acquisition (in shares)																																																									110,000
Investment in Subsidiary pursuant to Helomics 20% acquisition																																																									$ 1,100																					$ 1,041,150																																										$ 1,042,250
Warrant exercises (in shares)																																																													14,539	50,467
Warrant exercises																																																													$ 145	$ 505																				$ 145,251	$ 504,160																																									$ 145,396	$ 504,665
Shares issued pursuant to a consultant contract @ 11.80 per share (in shares)																																																																								25,000
Shares issued pursuant to a consultant contract @ 11.80 per share																																																																								$ 250																					$ 294,750																																										$ 295,000
Shares issued in escrow pursuant to a contract with TumorGenesis @ 11.70 per share (in shares)																																																																									75,000
Shares issued in escrow pursuant to a contract with TumorGenesis @ 11.70 per share																																																																									$ 750																					$ 876,750																																										$ 877,500
Warrants issued																																																																																						$ 183,187		$ 68,757																																								$ 183,187		$ 68,757
Shares issued to employee in lieu of bonus (in shares)																																																																												4,341
Shares issued to employee in lieu of bonus																																																																												$ 44																					40,194																																										40,238
Vesting Expense																																																																																																	1,124,928																																										1,124,928
Net loss																																																																																																																						(10,086,477)																					(10,086,477)
Balance (in shares) at Dec. 31, 2018																					79,246																																																							1,409,175
Balance at Dec. 31, 2018																					$ 792																																																							$ 14,092																					63,146,533																					(63,107,945)																					53,472
Preferred conversion to common shares pursuant to private placement agreement
Preferred conversion to common shares pursuant to private placement agreement (in shares)																																																																					103,415	30,000	8,857
Preferred conversion to common shares pursuant to private placement agreement																																																																					$ 1,034	$ 300	$ 89																			$ 377,539	$ 127,200	$ 130,129																																								$ 378,573	$ 127,500	$ 130,218
Shares issued (in shares)																																																								7,813		919,929		122,356																																																															122,356
Shares issued																																																								$ 78		$ 9,200		$ 1,224																	$ 49,922		$ 5,263,818		$ 317,972																																						$ 50,000		$ 5,273,018		$ 319,196
Investment in Subsidiary pursuant to Helomics 20% acquisition (in shares)																																	3,500,000																																											400,000
Investment in Subsidiary pursuant to Helomics 20% acquisition																																	$ 35,000																																											$ 4,000																					5,573,250																																										5,612,250
Warrant exercises (in shares)																																																																												59,700
Warrant exercises																																																																												$ 597																					5,373																																										5,970
Shares issued pursuant to a consultant contract @ 11.80 per share (in shares)																																																																										10,356
Shares issued pursuant to a consultant contract @ 11.80 per share																																																																										$ 103																					$ 34,820																																										$ 34,923
Warrants issued																																																																																				$ 180,640	$ 356,471		$ 6,261,590		$ 177,343																																					$ 180,640	$ 356,471		$ 6,261,590		$ 177,343
Vesting Expense																																																																																																	2,250,422																																										2,250,422
Net loss																																																																																																																						(19,390,766)																					(19,390,766)
Shares issued in forbearance agreement (in shares)																																																																												16,667
Shares issued in forbearance agreement																																																																												$ 166																					158,183																																										158,349
Stock issued to extinguish debt as part of Helomics purchase consideration (in shares)																																																																												863,732
Value of shares to extinguish debt (iii)																																																																												$ 8,637																					6,454,672																																										6,463,309
Issuance of Series E preferred shares (in shares)																																													258
Issuance of Series E preferred shares																																													$ 3																																																				2,338,837																																										2,338,840
Inducement shares issued pursuant to equity line (in shares)																																																																												104,652
Inducement shares issued pursuant to equity line																																																																												$ 1,047																					448,953																																										450,000
Balance (in shares) at Dec. 31, 2019																					79,246												3,500,000												258																															4,056,652
Balance at Dec. 31, 2019																					$ 792												$ 35,000												$ 3																															$ 40,567																					$ 93,653,667																					$ (82,498,711)																					$ 11,231,318